Umbilical cord blood therapy offers hope for children with cerebral palsy (CP).
Doctors infuse cells from umbilical cord blood (UCB) intravenously. These cells come from the child’s own stored cord blood (autologous) or from donors (allogeneic).
Researchers focus on young children. They aim to reduce inflammation and support brain repair through paracrine effects.
A major 2025 meta-analysis combined data from 11 trials. It included over 400 children.
Children receiving UCB plus rehabilitation improved gross motor function more than those with rehabilitation alone. For example, GMFM-66 scores rose by about 1.4 points at 6 and 12 months.
Higher cell doses produced stronger benefits. Younger children and those with milder CP often responded best.
Trials confirm strong safety. Serious side effects occur at similar rates in treated and control groups.
Duke University leads much of this work. They offer expanded access infusions for eligible patients up to age 26.
Ongoing studies explore combinations like UCB with erythropoietin or mesenchymal cells.
Overall, UCB therapy shows real promise. It improves motor skills beyond standard care, especially with early and higher-dose treatment.
However, experts call for larger phase 3 trials. These will confirm long-term effects and refine protocols.